MD1533Z - Пищевая фитотерапевтическая добавка антиSARS-CoV-2 - Google Patents
Пищевая фитотерапевтическая добавка антиSARS-CoV-2 Download PDFInfo
- Publication number
- MD1533Z MD1533Z MDS20200128A MDS20200128A MD1533Z MD 1533 Z MD1533 Z MD 1533Z MD S20200128 A MDS20200128 A MD S20200128A MD S20200128 A MDS20200128 A MD S20200128A MD 1533 Z MD1533 Z MD 1533Z
- Authority
- MD
- Moldova
- Prior art keywords
- root
- sars
- aerial part
- cov
- phytotherapeutic
- Prior art date
Links
- 235000015872 dietary supplement Nutrition 0.000 title claims abstract description 21
- 240000003291 Armoracia rusticana Species 0.000 claims abstract description 10
- 235000011330 Armoracia rusticana Nutrition 0.000 claims abstract description 10
- 235000003261 Artemisia vulgaris Nutrition 0.000 claims abstract description 10
- 235000009496 Juglans regia Nutrition 0.000 claims abstract description 10
- 241000212322 Levisticum officinale Species 0.000 claims abstract description 10
- 239000001645 levisticum officinale Substances 0.000 claims abstract description 10
- 241001426527 Rhaponticum Species 0.000 claims abstract description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 8
- 235000009051 Ambrosia paniculata var. peruviana Nutrition 0.000 claims abstract description 7
- 235000003097 Artemisia absinthium Nutrition 0.000 claims abstract description 7
- 235000017731 Artemisia dracunculus ssp. dracunculus Nutrition 0.000 claims abstract description 7
- 239000001138 artemisia absinthium Substances 0.000 claims abstract description 7
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims abstract description 7
- 235000020234 walnut Nutrition 0.000 claims abstract description 7
- 244000205574 Acorus calamus Species 0.000 claims abstract description 5
- 235000019441 ethanol Nutrition 0.000 claims abstract description 5
- 239000008213 purified water Substances 0.000 claims abstract description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 5
- 235000006480 Acorus calamus Nutrition 0.000 claims abstract description 4
- 240000007049 Juglans regia Species 0.000 claims abstract description 4
- 244000067505 Xanthium strumarium Species 0.000 claims abstract description 4
- 239000012675 alcoholic extract Substances 0.000 claims abstract description 3
- 238000000605 extraction Methods 0.000 claims abstract description 3
- 240000006891 Artemisia vulgaris Species 0.000 claims description 9
- 241000758789 Juglans Species 0.000 claims description 6
- 239000004615 ingredient Substances 0.000 claims description 5
- 235000004355 Artemisia lactiflora Nutrition 0.000 claims description 3
- 235000013832 Valeriana officinalis Nutrition 0.000 claims description 2
- 244000126014 Valeriana officinalis Species 0.000 claims description 2
- 235000016788 valerian Nutrition 0.000 claims description 2
- 230000003078 antioxidant effect Effects 0.000 abstract description 18
- 241001678559 COVID-19 virus Species 0.000 abstract description 17
- 239000003963 antioxidant agent Substances 0.000 abstract description 11
- 230000003308 immunostimulating effect Effects 0.000 abstract description 10
- 230000005764 inhibitory process Effects 0.000 abstract description 6
- 239000003814 drug Substances 0.000 abstract description 3
- 235000013305 food Nutrition 0.000 abstract description 3
- 240000001851 Artemisia dracunculus Species 0.000 abstract 1
- 238000011282 treatment Methods 0.000 description 13
- 239000000203 mixture Substances 0.000 description 10
- 239000013589 supplement Substances 0.000 description 9
- 108010053070 Glutathione Disulfide Proteins 0.000 description 6
- YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 description 6
- YPZRWBKMTBYPTK-UHFFFAOYSA-N oxidized gamma-L-glutamyl-L-cysteinylglycine Natural products OC(=O)C(N)CCC(=O)NC(C(=O)NCC(O)=O)CSSCC(C(=O)NCC(O)=O)NC(=O)CCC(N)C(O)=O YPZRWBKMTBYPTK-UHFFFAOYSA-N 0.000 description 6
- QRYRORQUOLYVBU-VBKZILBWSA-N Carnosic acid Natural products CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 description 5
- 108010087806 Carnosine Proteins 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- CQOVPNPJLQNMDC-UHFFFAOYSA-N N-beta-alanyl-L-histidine Natural products NCCC(=O)NC(C(O)=O)CC1=CN=CN1 CQOVPNPJLQNMDC-UHFFFAOYSA-N 0.000 description 5
- 229940044199 carnosine Drugs 0.000 description 5
- CQOVPNPJLQNMDC-ZETCQYMHSA-N carnosine Chemical compound [NH3+]CCC(=O)N[C@H](C([O-])=O)CC1=CNC=N1 CQOVPNPJLQNMDC-ZETCQYMHSA-N 0.000 description 5
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 5
- 230000000840 anti-viral effect Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 108010024636 Glutathione Proteins 0.000 description 3
- 208000036142 Viral infection Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 208000010470 Ageusia Diseases 0.000 description 2
- 206010002653 Anosmia Diseases 0.000 description 2
- 208000025721 COVID-19 Diseases 0.000 description 2
- 206010008479 Chest Pain Diseases 0.000 description 2
- 241000711573 Coronaviridae Species 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 206010068319 Oropharyngeal pain Diseases 0.000 description 2
- 201000007100 Pharyngitis Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 208000036071 Rhinorrhea Diseases 0.000 description 2
- 206010039101 Rhinorrhoea Diseases 0.000 description 2
- 235000001466 Ribes nigrum Nutrition 0.000 description 2
- 241001312569 Ribes nigrum Species 0.000 description 2
- 208000037847 SARS-CoV-2-infection Diseases 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 208000017574 dry cough Diseases 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229960003180 glutathione Drugs 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 210000003300 oropharynx Anatomy 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- DBHODFSFBXJZNY-UHFFFAOYSA-N 2,4-dichlorobenzyl alcohol Chemical compound OCC1=CC=C(Cl)C=C1Cl DBHODFSFBXJZNY-UHFFFAOYSA-N 0.000 description 1
- 235000011996 Calamus deerratus Nutrition 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 208000035859 Drug effect increased Diseases 0.000 description 1
- 241000709661 Enterovirus Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 241000241413 Propolis Species 0.000 description 1
- 235000011483 Ribes Nutrition 0.000 description 1
- 241000220483 Ribes Species 0.000 description 1
- 235000016954 Ribes hudsonianum Nutrition 0.000 description 1
- 241000315672 SARS coronavirus Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 235000005865 Symphytum officinale Nutrition 0.000 description 1
- 240000002299 Symphytum officinale Species 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- CKGWFZQGEQJZIL-UHFFFAOYSA-N amylmetacresol Chemical compound CCCCCC1=CC=C(C)C=C1O CKGWFZQGEQJZIL-UHFFFAOYSA-N 0.000 description 1
- 229960005213 amylmetacresol Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 229940064004 antiseptic throat preparations Drugs 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229960004698 dichlorobenzyl alcohol Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- ZCGNOVWYSGBHAU-UHFFFAOYSA-N favipiravir Chemical compound NC(=O)C1=NC(F)=CNC1=O ZCGNOVWYSGBHAU-UHFFFAOYSA-N 0.000 description 1
- 229950008454 favipiravir Drugs 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 230000035987 intoxication Effects 0.000 description 1
- 231100000566 intoxication Toxicity 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 229940069949 propolis Drugs 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000000614 rib Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000000101 thioether group Chemical group 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Изобретение относится к пищевой промышленности, санокреатологии и медицине, в частности к биологически активной, фитотерапевтической пищевой добавке, обладающей антиоксидантной, иммуностимулирующей активностью, с ингибированием вируса SARS-CoV-2.Пищевая добавка, согласно изобретению, содержит спиртовой экстракт из: надземной части полыни, надземной части дурнишника, корня марала, кожуры грецкого ореха, корня хрена, надземной части любистка и корня аира болотного, полученный экстракцией 96,4% об.-ным этиловым спиртом, в соотношении 1:(4-5) соответственно, в течение 15-21 суток, а также очищенную воду, остальное, до достижения крепости 32-35% об.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MDS20200128A MD1533Z (ru) | 2020-10-09 | 2020-10-09 | Пищевая фитотерапевтическая добавка антиSARS-CoV-2 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MDS20200128A MD1533Z (ru) | 2020-10-09 | 2020-10-09 | Пищевая фитотерапевтическая добавка антиSARS-CoV-2 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MD1533Y MD1533Y (ru) | 2021-05-31 |
| MD1533Z true MD1533Z (ru) | 2021-12-31 |
Family
ID=76191341
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MDS20200128A MD1533Z (ru) | 2020-10-09 | 2020-10-09 | Пищевая фитотерапевтическая добавка антиSARS-CoV-2 |
Country Status (1)
| Country | Link |
|---|---|
| MD (1) | MD1533Z (ru) |
-
2020
- 2020-10-09 MD MDS20200128A patent/MD1533Z/ru not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| MD1533Y (ru) | 2021-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Roxas et al. | Colds and influenza: a review of diagnosis and conventional, botanical, and nutritional considerations. | |
| Ndhlala et al. | Toxicology of some important medicinal plants in southern Africa | |
| US6576267B2 (en) | Composition and method for treating the effects of diseases and maladies | |
| CN100553665C (zh) | 一种治疗咽喉炎的中药药物 | |
| CN113208020A (zh) | 一种提高人体免疫力的植物保健饮料 | |
| TW201827044A (zh) | 用於治療發炎性腸病的組合物 | |
| MD1533Z (ru) | Пищевая фитотерапевтическая добавка антиSARS-CoV-2 | |
| MD1531Z (ru) | Пищевая фитотерапевтическая добавка антиSARS-CoV-2 | |
| MD1532Z (ru) | Пищевая фитотерапевтическая добавка антиSARS-CoV-2 | |
| Watson | Some observations on the effect of blueberry leaf extract in diabetes mellitus | |
| MD1629Z (ru) | Фитотерапевтическая пищевая добавка против SARS-CoV-2 | |
| US20080254071A1 (en) | Homeopathic composition for alleviating allergy symptoms | |
| CN105451749B (zh) | 吸附雄蜂幼虫匀浆和维生素d3或d族维生素和/或其活性代谢物在病毒性疾病的预防和治疗中的应用 | |
| RU2410096C1 (ru) | Способ лечения больных псориазом в сочетании с хроническим описторхозом | |
| MD1541Z (ru) | Метод лечения инфекции вирусом SARS-CoV-2 средней формы | |
| RU2776878C1 (ru) | Способ комбинированного лечения клещевого риккетсиоза, обусловленного Хейлунцзянской риккетсией, органическим селеном | |
| JP2009263384A (ja) | Ｉ型アレルギー性疾患のアトピー性皮膚炎の症状を抑制するための内服薬 | |
| CN116392476A (zh) | 协同抑制胰脂肪酶的组合物及其应用 | |
| CN106975026A (zh) | 一种清咽利喉的中药雾化剂及药剂盒 | |
| Joshi et al. | Role of Vitamin-C, Vitamin-D and Zinc in Covid-19 Pandemic | |
| JP2024083774A (ja) | サプリメント | |
| RU2464034C2 (ru) | Способ лечения туберкулеза, осложненного непереносимостью химиотерапии | |
| Hosseini et al. | Management of Castor bean seed-associated intraventricular hemorrhage with fresh frozen plasma: a case report | |
| Josling | Allicin | |
| US9629887B1 (en) | Control of acid reflux with botanicals |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG9Y | Short term patent issued | ||
| KA4Y | Short-term patent lapsed due to non-payment of fees (with right of restoration) | ||
| MM4Y | Short-term patent definitely lapsed due to non-payment of fees |